Status:
COMPLETED
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Janssen, LP
Conditions:
Acute Ischemic Stroke
Transient Ischemic Attack (TIA)
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke preventio...
Eligibility Criteria
Inclusion
- Male and Female ≥40 years of age
- Acute Ischemic Stroke or Transient Ischemic Attack
- Intracranial or Extracranial Atherosclerotic Plaque proximal to the affected brain area
Exclusion
- Predicted inability to swallow study medication
- Any condition that, in the opinion of the Investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding
- Use of thrombolytic therapy or mechanical thrombectomy for treatment of index stroke
- Other protocol defined inclusion/exclusion criteria could apply
Key Trial Info
Start Date :
January 27 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
2366 Patients enrolled
Trial Details
Trial ID
NCT03766581
Start Date
January 27 2019
End Date
March 31 2022
Last Update
June 12 2023
Active Locations (424)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0029
Birmingham, Alabama, United States, 35233
2
Local Institution - 0007
Glendale, California, United States, 91206
3
Local Institution - 0006
Long Beach, California, United States, 90806
4
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States, 90027